T A Yap
Overview
Explore the profile of T A Yap including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piha-Paul S, Tseng C, Tran H, Naing A, Dumbrava E, Karp D, et al.
ESMO Open
. 2025 Feb;
10(2):104136.
PMID: 39908697
Background: The ErbB family of receptor tyrosine kinases are key targets for antitumor therapy. Although neratinib, a pan-ErbB kinase inhibitor, is approved in ErbB2-positive breast cancer, drug resistance is common....
2.
Yap T, Choudhury A, Hamilton E, Rosen L, Stratton K, Gordon M, et al.
ESMO Open
. 2024 Aug;
9(9):103653.
PMID: 39214047
Background: PF-06952229 is a selective small-molecule inhibitor of transforming growth factor-β (TGF-β) receptor 1. We evaluated its antitumor activity in preclinical studies and its safety, tolerability, pharmacokinetics, and pharmacodynamics in...
3.
Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, et al.
ESMO Open
. 2024 Jun;
9(6):103486.
PMID: 38914452
Background: Paclitaxel resistance limits durability of response in patients with initial clinical benefit. Overexpression of spleen tyrosine kinase (SYK) has been proposed as a possible resistance mechanism. This phase I...
4.
Maddalena G, Zeineddine F, Rivero-Hinojosa S, Aushev V, Chowdhury S, Zeineddine M, et al.
Ann Oncol
. 2024 May;
35(7):678-680.
PMID: 38734075
No abstract available.
5.
Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, et al.
Ann Oncol
. 2023 Aug;
34(11):1035-1046.
PMID: 37619847
Background: Human epidermal growth factor receptor 2 (HER2)-low is a newly defined category with HER2 1+ or 2+ expression by immunohistochemistry (IHC) and lack of HER2 gene amplification measured by...
6.
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, et al.
Ann Oncol
. 2022 Oct;
34(1):48-60.
PMID: 36182023
In 2021, the Food and Drug Administration Oncology Center of Excellence announced Project Optimus focusing on dose optimization for oncology drugs. The Methodology for the Development of Innovative Cancer Therapies...
7.
Pilie P, George A, Yap T
Ann Oncol
. 2020 Oct;
31(12):1603-1605.
PMID: 33011228
No abstract available.
8.
Ileana Dumbrava E, Mills G, Yap T
Ann Oncol
. 2018 Aug;
29(9):1889-1891.
PMID: 30084907
No abstract available.
9.
Weller A, OBrien M, Ahmed M, Popat S, Bhosle J, McDonald F, et al.
Eur J Cancer
. 2016 Mar;
59:65-78.
PMID: 27016624
Therapeutic options in locally advanced non-small cell lung cancer (NSCLC) have expanded in the past decade to include a palate of targeted interventions such as high dose targeted thermal ablations,...
10.
Khan K, Yap T, Ring A, Molife L, Bodla S, Thomas K, et al.
Br J Cancer
. 2016 Jan;
114(3):262-8.
PMID: 26757260
Background: This study had two aims: (a) to test the hypothesis that advanced age is associated with lower levels of tolerability and clinical benefit to experimental Phase I trial agents;...